InvestorsHub Logo
Followers 6
Posts 4111
Boards Moderated 0
Alias Born 12/14/2009

Re: None

Wednesday, 05/08/2019 4:04:56 PM

Wednesday, May 08, 2019 4:04:56 PM

Post# of 108191
The company's failure is due to the clinical trial data not being good enough relative to more promising cancer treatments in development that are attracting investor and pharma capital while interest in ADXS' LLM tech has evaporated because of the low chances it will ever have commercial success. Just ask Amgen why they bailed. Just ask Aduro why they shuttered their LLM program. Just ask yourself why ADXS why after two and a half years since declaring they were actively searching for an AXAL partner there have been no takers. Has nothing to do with hedge funds or ADXS management, but everything to do with the science.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News